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Prophylactic vaccination  against  pneumonia  has  been  practised 
with  apparent  success  on the  miners  in  South  Africa  by  Wright,  1 
and more recently by Lister2  Within the past 2 years similar investi- 
gations have been. undertaken in the  United States Army Camps by 
Cecil and  Austin  s  at  Camp Upton,  and  by Cecil and  Vaughan  4 at 
Camp  Wheeler.  The  results  obtained  in  these  later  experiments 
were  so  encouraging  that  the  whole  question  of  active  immunity 
against pneumococcus seemed worthy of thorough study. 
It has long been recognized that injection into animals  of killed cultures of 
pneumococcus would protect them against lethal doses of living virulent pneu- 
mococci injected intravenously.  Animals vaccinated in this way usually develop 
agglutinins  and protective substances  in their sera.  Dochez  5 has shown that  in 
man protective bodies are usually demonstrable in the serum of a patient im- 
mediately following an attack of pneumonia; and Cecil and Austin  s found that 
the injection of killed pneumococci in man would, in some cases at least, stimulate 
the production of agglutinins and protective bodies. 
* Wright, A. E., Lancet, 1914, i, 87. 
2  Lister, F. S., An experimental study of prophylactic inoculation against pneu- 
mococcal infection in the rabbit and in man,  Publications  of the South African 
Institute for Medical  Research, No. 8, Johannesburg,  1916; Prophylactic inocu- 
lation of man against pneumococcal  infections,  and more  particularly against 
lobar pneumonia, Publications  of the South African Institute for Medical  Re- 
search, No. 10,"  Johannesburg,  1917. 
3 Cecil, R. L., and Austin, J. H., J. Exp. Meal., 1918, xxv!ii, 19. 
4 Cecil, R. L., and Vaughan, H. F., J. Exp. Med., 1919, xxix, 457. 
5  Dochez, A. R., J. Exp. Med., 1912, xvi, 665. 
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In spite of the fact that the injection of killed cultures of pneumococcus in 
rabbits, horses, and other animals will protect these animals against lethal doses 
of the living organism, this accomplishment  is not equivalent to preventing the 
disease, pneumonia, itself.  Indeed, very little is known concerning the whole 
subject of active immunity against pneumonia and comparatively little experi- 
mental work has been done along this line. 
Wadsworth  6 immunized  eleven rabbits againstpneumococcus  by injecting them 
with pneumococci which had been  dissolved in rabbit  bile.  The  eleven im- 
munized rabbits and five controls were then injected intratracheally with I cc. 
of a virulent pneumococcus culture.  Of the five control animals, three died in 
48 hours without lung lesions; a fourth lived 4 days and a small patch of pneu- 
monia was found at autopsy.  The fifth was dying on the 5th day when it was 
killed.  A small area of consolidation was found in this  animal also.  Of the 
eleven immunized animals, none died, but a few were seriously ill from 24 to 36 
hours.  All the immunized animals, when kiUed, showed more or less extensive 
pulmonary consolidation. 
In  the  experiments referred to above, rather large doses of pneu- 
mococcus were used for infecting the animals, and it is probable that 
the controls were overwhelmed by the infection before there was an 
opportunity for pneumonia to develop.  It is  possible  that if smaller 
doses had been employed for the intratracheal injections, Wadsworth 
would  have produced pneumonia in the controls, and, on the other 
hand, the immunized animals would have escaped infection altogether. 
The  production  experimentally  of  typical  lobar  pneumonia  in 
monkeys affords an excellent method of testing the value of pneumo- 
coccus vaccine.  It has been shown  7,s that pneumococcus pneumonia 
in monkeys differs in no respect clinically or pathologically from pneu- 
mococcus pl~eumonia in man.  An inflammation of the lungs can be 
produced in  rabbits,  dogs,  and  other laboratory animals by intro- 
ducfng virulent pneumococci  or  streptococci into the trachea,  but 
animals injected in  this manner do  not  run  the  typical course  of 
lobar  pneumonia  as  observed  in  man.  The  object  of  the  present 
study has been to determine first the value of prophylactic pneumo- 
coccus vaccination in general, and secondly, the relative merits of the 
different types of pneumococcus vaccine that have been employed. 
6  Wadsworth, A., Am. J. Med. Sc., 1904, cxxvii, 851. 
7  Blake, F. G., and Cecil, R. L., J. Exp. Med., 1920, xxxi, 403. 
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Technique. 
All the vaccine employed in this study was monovalent and was 
prepared from an old culture of Pneumococcus  Type I which had been 
carried in the laboratory stock for several years.  This organism ap- 
peared to have lost practically all its virulence.  1 cc. of a  24 hour 
broth  culture had  no  effect whatever  on  a  mouse when injected 
intraperitoneally,  This was the same culture which was used at the 
Army Medical School  in  the preparation of pneumococcus vaccine 
for army camps. 
The culture used for infecting the monkeys was a highly virulent 
Pneumococcus Type I, originally isolated from a case of lobar pneu- 
monia.  This organism killed a mouse in doses of 0.0000001 cc., and 
0.00000001 cc. was usually lethal. 
Method  of  Producing  Experimental  Pneumonia.--Experimental 
pneumonia was produced by introducing a  small quantity of an  18 
hour broth culture of pneumococcus (0.000001 to 1 cc.) with a Luer 
syringe directly into the trachea by the method previously described,  r 
Symptoms of pneumonia developed 24  to 48  hours after injection. 
In testing for resistance to  infection following  pneumococcus vac- 
cination, the animals were injected intratracheaHy, in most  cases  2 
to 4 weeks after vaccination. 
Experiments with Pneumococcus Type I  Lipovaccine. 
The first  vaccine to be  experimented with was a  Pneumococcus 
Type I  lipovaccine which had been prepared at the Army Medical 
School according to the process described by Whitmore, Fennel, and 
Petersen.  9 
18  hour  glucose  broth  cultures  of  Pneumococcus Type  I  were 
centrifuged in  a  Sharpless  machine.  The  sediment was  dried  at 
53°C.  for  24  hours.  This  killed  all  the  pneumococci.  The dried 
sediment was then weighed and ground with steel balls for 24 hours. 
9  Whitmore, E. R., Fennel, E. A., and Petersen, W. F., J. Am. Med. Assn., 
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Finally,  the dry powder was suspended in cottonseed oil containing 
2 per cent lanolin and diluted to the desired strength. 1° 
Dosage.--In  order  to make  the  results  comparable  with  those  in 
man  only  one  injection  of  lipovaccine  was  administered  to  each 
monkey.  As in man,  the vaccine was injected  subcutaneously,  the 
abdominal wall being the site of inoculation. 
Two series  of monkeys were vaccinated;  the  first  series  received 
each the same dose that a  man received of Pneumococcus Type I  in 
the triple pneumococcus lipovaccine prepared by the Army Medical 
School; that is,  16 billion pneumococci, or 0.8 rag.  of the dried bac- 
teria.  The second series received a dose proportional to their weight 
as compared with the weight of man.  The average weight of a man 
is  70  kilos;  the  average  weight  of  a  Philippine  monkey is  4  kilos. 
This series therefore received ~  of man's dose, or  1 billior/" pneumo- 
cocci (0.05 rag.  of the dried bacteria).  The lipovaccine was always 
diluted  so  that  the  monkey received  1  cc.  of  the  oily  suspension. 
In  the  first  experiment  a  lipovaccine was used which  was  about 4 
months old.  In the remainder of the experiments, however, a freshly 
prepared vaccine was substituted. 
Preliminary  Test of Pneumococcus Lipovaccine.--The  first attempt 
to  test  the  efficacy  of  pneumococcus  lipovaccine  was  carried  out 
before the minimal infecting dose had been determined.  As a result, 
the  infecting  dose  which  was  employed  in  this  experiment  was  1 
million times the size actually necessary to infect a  normal monkey. 
The  experiment is reported,  tmwever,  as it illustrates  certain  differ- 
ences between pneumonia in vaccinated and unvaccinated monkeys. 
Experiment /.--Three Macacus syrichtus monkeys were used in this  experi- 
ment (Table I).  Monkey 14 had received  a large  dose  (16 billion) of Pneu- 
mococcus  Type I lipovaccine, Monkey 17 a small dose (1 billion) of the same, while 
Monkey 27 served as a control.  On Mar. 26, 1919, each of these three monkeys 
received  1 cc. of an 18 hour broth cultureof PneumococcusTypelintratracheally. 
The results are shown in Table I and Text-fig. 1.  All three monkeys died; the 
vaccinated monkeys, however, lived longer than the control  Monkey 14, which 
t0 For full details for the method of preparing lipovaccine see articles by Whit- 
more,  Fennel,  and  Petersen, ~ Whitmore  and  Fennel  (Whitmore,  E.  R.,  and 
Fennel, E. A., J. Am. Med. Assn., 1918, lxx, 1902), and Fennel (Fennel, E. A., 
J. Am. Med. Assn., 1918, lxxi, 2115). RUSSELL  L.  CECIL  AND  ~RANCIS  O.  BLAKE 
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received a  large dose of vaccine, had apparently recovered on Apr. 10, but died 
suddenly on Apr. 12  from a greatly dilated heart.  The leucocyte reactions were 
more marked in  the  vaccinated monkeys, though  there  was  not  a great deal 
of  difference  between  Monkeys  17  and  27.  Finally,  the  blood  culture  in 
Monkey 14, which received a large dose of vaccine, remained practically sterile, 
while in the othe~ two monkeys the blood contained large numbers of pneum  0- 
cocci.  The control monkey was overwhelmed by the huge infecting dose and 
died before frank pneumonia developed.  He showed, in addition to hemorrhagic 
bronchitis  , acute suppurative pericarditis. 
In  this  experiment  vaccination  failed  to  protect  either  monkey 
against  pneumonia,  but  the  results  in  the  case  of  one vaccinated 
monkey suggested that vaccination had modified to some extent the 
virulence of the infection. 
Effecl  of Small Doses of Pneumococcus Lipovaccine.--If protection 
against  pneumococcus  infection  in  monkeys  could  be  obtained  by 
vaccination,  it  was  desirable  to  find  the  minimum  efficient  dose;  in 
other words, a  dose that would be comparable with that used in man. 
In  the  following  experiment  the  vaccinated  monkeys  had  each  re- 
ceived a  dose of lipovaccine proportional to their weight as compared 
with the weight of a  man; that is, 0.05. rag. of  the dried bacteria, or 1 
billion pneumococci~ 
Experiment 2.--Six Macacus syrichtus monkeys were used in this experiment. 
Three (Monkeys 64,  65,  and 67)  had received 1 billion each of Pneumococcus 
Type I  lipovaccine;  the  other  three  (Monkeys 85,  86,  and  87)  were  controls 
(Table II).  May 6, 1919.  All six monkeys were injected.intratracheally with an 
18 hour broth culture of Pneumococcus Type I.  Monkeys 65 and 87 received 0.1 
cc.; Nos. 67 and 85 received 0.001 cc.; and Nos. 64 and 86 received 0.000001 cc. 
All  six  monkeys promptly developed symptoms of pneumonia.  It will  be 
observed, however, that while the three control monkeys died,, two of the vac- 
cinated monkeys recovered.  The third vaccinated monkey (No. 67) had a crisis 
on  the 9th  day, but died suddenly on the  llth  day of the disease. ' Autopsy 
revealed an old aortic endocarditis and insufficiency,  with  cardiac hypertrophy 
and dilatation.  The size of the dose did not appear to exert a very pronounced 
ilxfluence on the course of the disease in either vaccinated or unvaccinated mon- 
keys.  Table II shows  the protocols of these experiments, and Text-figs. 2, 3, 
and 4 exhibit the temperature, leucocyte, and blood culture curves. 526  EXPER  TMENTAL PNEUMONIA.  IV 
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In these experiments, as in Experiment 1, it will be observed that 
the blood culture was sterile or weakly positive in vaccinated mon- 
keys, whit~all the  controls showed persistently positive blood  cul- 
tures.  These charts, however, demonstrate clearly that small doses 
of pneumococcus lipovaccine do not protect monkeys against pneu- 
mococcus pneumonia,  even  when  the  infecting dose is  very small. 
It will also be  observed  that lipovaccine failed to  stimulate agglu- 
tinins or protective substances in the monkeys' blood.  Nevertheless, 
vaccination did appear to influence favorably the course of the disease. 
Effect of Large Doses of Pneumococcus Lipovaccine.--In  view of the 
failure of small doses of  lipovaccine to protect against pneumonia, 
the next step was to determine the effect of large doses of pneumo- 
coccus  lipovaccine.  This experiment was carried  out  in  the  same 
manner as the one just described. 
Experiment 3.--Six Macacus syricktus  monkeys were tested in this experiment 
(Table III, Text-figs. 5, 6, and  7).  Monkeys 78,  80,  and  81. had been  vac- 
cinated, each with 16 billion pneumococci.  Monkeys 93, 95, and 96 were used 
for controls.  All six monkeys  were inoculated intratracheally with an 18 hour 
broth culture of Pneumococcus Type I.  Monkeys 81  and  95 received 0.00001 
cc., and Monkeys 80 and 96 received 0.000001 cc. on May 13, 1919.  Monkeys 
78 and 93 received 0.001 cc. on May 15.  All six monkeys  developed  pneumonia. 
In this experiment two of the controls and two of the vaccinated monkeys re- 
covered, while one in each series died.  The death of the vaccinated monkey was 
unquestionably due  to the complicating pericarditis which was discovered at 
autopsy. 
As  in  Experiment  2,  the  vaccinated  monkeys showed  sterile  or 
weakly positive blood  cultures,  with  the  exception of  Monkey 80, 
in  which  the  development of  pericarditis  probably  contributed  to 
the production of a  fairly heavy blood infection.  The character of 
the leucocyte reaction did not appear to be influenced by vaccination, 
nor was the disease appreciably shortened in the vaccinated group. RUSSELL  L. CECIL AND  ]~RANCIS  G. BLAKE  531 
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Contact Experiments. 
From the preceding experiments it is evident that pneumococcus 
lipovaccine in the dosage employed failed to protect monkeys against 
experimental pneumonia.  In order, however, to  forestall  the  criti- 
cism which might be made that pneumonia had been produced  by 
artificial means, it was decided to test the immunity of the vaccinated 
monkeys against spontaneous pneumonia by means of a contact test. 
gO  i30  3!  /  ~  3  ¢  ~  ~  7  8  ?  tO  13  !/g 
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TEXT-FIG. 8.  Spontaneous  Pneumococcus Type I  pneumonia  developing in 
Monkey 16, vaccinated on Mar. 11 with a large dose (16 billion) of Pneumococcus 
Type  I  lipovaccine  subcutaneously.  Infection  followed  contact  in  the  same 
cage with another case of Pneumococcus Type I  pneumonia. 
Experiment  4.--Three Macacus  syrichtus  monkeys which had previously been 
vaccinated  with  pneumococcus  lipovaccine  were  placed  in  a  cage  with  three 
normal healthy  monkeys.  Two monkeys in  the  active  stage of Pneumococcus RUSSELL  T.. CECIL AND  FRANCIS  G. BLAKE  537 
Type I pneumonia were then put in the cage with the other six monkeys  and the 
eight animals kept in intimate contact for 2 weeks.  A few days after the experi- 
ment was started,  Monkey 16, one of the vaccinated animals, became ill with 
pneumonia.  The protocol follows: 
Mar. 11, 1919.  Monkey 16, Macacus syrichtus; weight 3,630 gm.  Received 
0.8 rag. (16 billion) of Pneumococcus  Type I lipovaccine subcutaneously.  May 
26.  Monkey placed in the same cage with two other vaccinated monkeys, three 
normal monkeys and two monkeys suffering with Pneumococcus Type I pneu- 
monia.  June 6.  Monkey appears sick; marked leucocytosis.  Blood culture 
shows Pneumococcus  Type I.  June 7.  Typical lobar pneumonia; blood culture 
shows 650 colonies of Pneumococcus Type I  per  0.5  cc.  of blood.  June  11. 
Marked improvement.  Monkey has run a typical course of lobar pneumonia. 
TMs experiment shows that M0nk~y 16,  in spite of having been 
vaccinated  with  a  large  dose  of  pneumococcus  lipovaccine,  was 
unable to resist infection with Pneumococcus Type I  when exposed 
to  pneumonia due  to  this  type.  It  will be  observed,  however,  in 
Text-fig. 8, that the disease ran a mild and fairly short course, which 
supports the observation previously made that vaccinated monkeys 
tolerate  pneumonia  more  readily  than  unvaccinated  animals. 
Strangely  enough,  another  one  of  the  vaccinated  animals  in  the 
contact test developed pneumonia, but in this instance the infection 
proved to be with Pneumococcus Type .IV.  u  None of the control 
monkeys became infected. 
Spontaneous Pneumococcus Type IV Pneumonia in Monkeys  Vac- 
cinated against Pneumococcus Type  /.--Some  of  the  monkeys that 
had  been  inoculated with  Pneumococcus Type  I  lipovaccine were 
put back into a  large cage with a  number of stock monkeys.  An 
epidemic  of Pneumococcus Type IV  pneumonia broke  out  in  this 
cage and a number of the vaccinated monkeys contracted the disease. 
Experiment 5.--Three  Macacus syricktus monkeys (Nos. 13,  15, and 21) had 
received a small dose of Pneumococcus Type I lipovaccine (Table IV).  Pneu- 
monia developed spontaneously in all of them 4 to 7 weeks after vaccination, just 
at the time when presumably their immunity should have been at a high point. 
In Monkeys 13 and 15 Pneumococcus Type IV was recovered from  the autopsy 
cultures, and in Monkey 21 a pneumococcus was seen in the pericardial fluid, 
but failed to grow in the culture. 
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The protocols demonstrate the fact that monkeys vaccinated with 
Pneumococcus  Type  I  lipovaccine possess  no  demonstrable  cross- 
immunity against spontaneous Pneumococcus Type IV pneumonia. 
Summary of Lipovacdne Experiments.--A review of the experiments 
so far reported brings out these facts: 
1.  Pneumococcus Type  I  lipovaccine,  whether  used  in  large  or 
small doses has failed to protect monkeys against experimental and 
spontaneous Pneumococcus Type I  pneumonia. 
2.  Vaccination, however, does  appear  to  modify the  course of a 
subsequent Type I pneumonia.  The blood is not so heavily infected 
as  in  unvaccinated  animals,  in  some  cases  remaining  practically 
sterile  throughout the  entire  course  of  the  disease.  Furthermore, 
the mortality rate is lower in the vaccinated monkeys and the disease 
seems to run a milder course. 
3.  No agglutinins or  protective bodies were demonstrated in any 
of the monkeys inoculated with lipovaccine. 
4.  There  is  no  evidence  that  Pneumococcus Type  I  lipovaccine 
confers  any  cross-immunity against  other  types  of  pneumococcus 
pneumonia. 
Experiments with Pneumococcus Type  I  Saline Vaccine. 
The  failure  of  pneumococcus  lipovaccine  to  protect  monkeys 
against pneumonia prompted us to test the value of pneumococcus 
saline vaccine.  Such experiments seemed all  the more justified in 
view of the fact that the results of prophylactic vaccination against 
pneumonia at  Camp Upton, where a  saline vaccine had been used, 
were distinctly better than the  results at  Camp Wheeler where the 
lipovaccine had been employed. 
The  pneumococcus saline  vaccine  was  prepared  from  the  same 
avirulent strain of Pneumococcus Type I  which had been used in the 
preparation  of  the  Pneumococcus Type I  lipovacclne.  The  saline 
vaccine was made as follows: 
Pneumococci were  cultivated for  18  hours in  glucose broth  and 
submitted  to  centrifugation.  The  bacterial  sediment  was  then 
heated at 55°C. for 1 hour to kill the pneumococci.  The vaccine was 
diluted with normal salt solution containing 0.25  per cent tricresol RUSSELL  L.  CECIL  AND  FRANCIS  G.  BLAKE  539 
and standardized by Wright's method.  The saline vaccine used in 
the following experiments was prepared  on May 1,  and the experi- 
ments were started on May 6, 1919. 
For the most part, the dosage and method of administration in the 
experiments with pneumococcus saline vaccine were the same as in 
the  lipovaccine  tests.  In  the  following experiments  each  monkey 
received only one subcutaneous injection. 
Results of Vaccination  with Pneumococcus  Type I  Saline  Vacdne.-- 
In testing the saline vaccine the effect of the large and small dosage 
was determined in one experiment. 
Experiment 6.--Four Macacus syrichtus monkeys were used in this experiment 
(Table V, Text-figs. 9 and 10).  Monkeys 88 and 89 had each been vaccinated 
with 1 billion, Monkey 90 with 16 billion Pneumococcus Type I saline vaccine. 
Monkey 98  was  the  control.  2 weeks after  these  monkeys were  vaccinated, 
their blood was tested  for agglutinins and protective bodies.  No agglutinins 
could be demonstrated, lJut all three monkeys showed the presence of protective 
bodies.  In Monkeys 89 and 90 the protection was marked, in Monkey 88 slight. 
2 weeks after vaccination the monkeys were injected intratracheally with an 18 
hour broth culture of Pneumococcus Type I.  Monkeys 88, 90, and 98 received 
each 0.000001 cc. of culture.  Monkey 89 received 0.001 cc. of culture.  The 
results are shown in Table V.  While  the four monkeys all developed  pneumonia, 
the control monkey ran a rapid course and died on the 4th day.  The vaccinated 
animals lived longer and two of them recovered (Monkeys 89 and 90).  Monkey 
88 died on the 5th day.  The two cases that terminated fatally showed extensive 
lobar pneumonia at autopsy and Pneumococcus Type I was recovered from the 
lungs and heart's  blood.  One of the vaccinated monkeys that recovered was 
killed and at autopsy showed a resolving pneumonia, cultures from which were 
sterile.  The  temperature,  leucocyte, and  blood culture  curves are  shown in 
Text-figs. 9 and 10. 
With  pneumococcus  saline  vaccine  as  with lipovaccine, prophy- 
lactic inoculation failed to protect monkeys against'pneumonia, but, 
as in the case of lipovaccine, inoculation seemed to modify favorably 
the course of the disease.  The vaccinated monkey that died (Mon- 
key 88) was the one which showed the smallest amount of protective 
substances  in  its  blood.  The  two  vaccinated  monkeys which  re- 
covered showed only a  moderate degree of bacteremia, whereas the 
two monkeys that died had heavy blood infections.  The amount of 
pneumococcus culture used for infecting the monkeys appears to have 540  EXPERIMENTAL  PNEUMONIA.  IV 
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little influence, up to a  certain point, upon the course of the disease. 
Monkey  88  received  only  0.000001  cc.  and  died  on  the  5th  day. 
Monkey 89  received 0.001  cc.  (a  thousand  times  as  large  a  dose) 
and recovered from the infection after  running a comparatively  mild 
course. 
Results of Vaccination with Three Injections of Pneumococcus Type 
I  Saline  Vaccine.--Although  one  injection of  pneumococcus saline 
vaccine  failed  to  protect  monkeys  against  pneumococcus infection, 
the results  were rather  more  encouraging  than  those obtained with 
the lipovaccine.  In  two of the  vaccinated  monkeys tested,  a  high 
degree  of  protection  was  demonstrable  in  the  blood  following  the 
inoculation,  and although  these two monkeys both contracted pneu- 
monia,  the disease ran  a  mild  course and both monkeys recovered. 
Therefore it seemed desirable to determine whether three injections 
of pneumococcus saline  vaccine given  at intervals  of  1 week would 
not afford the necessary amount of protection. 
Experiment 7.--This series of Macacus syricktus  monkeys was started on saline 
vaccine May 22,  1919, each monkey receiving weekly subcutaneous injections 
of  1  billion pneumococci until  three  inoculations  had  been  given.  2 weeks 
after the third  injection the blood from these monkeys was tested for agglutinins 
and protective bodies.  No agglutinins or protective bodies could be demonstrated 
in any of the five  monkeys tested. 
June 20.  Two of the vaccinated monkeys and a control monkey were injected 
intratracheally  with 0.000001 ce. of an 18 hour broth  culture  of Pneumococcus 
Type I.  Table VI and Text-fig. 11 show the results obtained.  All three mon- 
keys developed pneumonia, and in all three the disease was fatal.  In one vac- 
cinated monkey (Monkey 100) the disease presented features which are usually 
associated with a mild attack; namely, a moderate infection of the blood and a 
good secondary rise in the leucocytes, while in the other (Monkey 101) a septi- 
cemia equally as heavy as that of the control developed.  At autopsy all three 
monkeys showed lobar  pneumonia,  and Pneumococcus Type I  was recovered 
from the organs. 
In  this  experiment  three  small  doses  of saline  vaccine  failed  to 
give as much  protection as had  been obtained by a  large  single in- 
jection in  the previous experiments. 
Summary  of Saline  Vaccine Experiments.--The experiments  which 
have been reported indicate that saline vaccine llke lipovaccine, when 
injected  subcutaneously  in  moderate  doses,  has  failed  to  protect 544  EX.PERTMEI~AL PNEUMONIA.  IV 
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monkeys  against  pneumococcus  pneumonia.  As  for  any  relative 
superiority  of one vaccine over the  other,  there  appears  to be little 
choice between the two.  Saline vaccine,  however, is more likely to 
stimulate  the  formation  of protective  bodies in  the  blood,  and  for 
this reason probably gives a  somewhat better immunity.  The indi- 
vidual  variation,  in  the  natural  resistance  of monkeys  to  pneumo- 
coccus infection is a factor of primary importance and one which must 
always be considered.  No definite decision can be reached as to the 
relative  merits  of  pneumococcus  lipovaccine  and  saline  vaccine, 
except by testing a large series of monkeys with each type. 
Effect  of Intravenous  Injection of Living Pneumococcus  Type I  Cul- 
tures  in  Monkeys  Vaccinated  wilh Pneumococcus 
Type I  Vaccine. 
In  the  preceding  experiments  it  has  been  shown  that  pneumo- 
coccus  vaccine  does  not  protect  monkeys  against  intratracheai  in- 
fection with pneumococcus.  It  seemed desirable,  therefore,  for the 
sake of comparison,  to determine whether these vaccinated monkeys 
would be protected against intravenous infection. 
Experiment 8.--July 8,  1919.  Two  Macacus syrichtus monkeys  that  had 
been vaccinated  4 weeks  previously with  three  injections  (1  billion each) of 
Pneumococcus Type I  saline  vaccine  and one  control  monkey  were injected 
intravenously  with 0.001 cc. of a broth culture of living virulent  Pneumococcus 
Type I.  This dose is often fatal for a normal monkey.  The results are shown 
in Table VII and Text-fig. 12.  The vaccinated monkeys showed few or no clinical 
symptoms  following the injection.  Monkey  105 remained perfectly  well, with 
sterile blood cultures.  Monkey  104, the other vaccinated  monkey, had a mild 
febrile reaction  and  a  temporary infection of the blood of 48 hours  duration. 
The control (Monkey 116) was ill for 6 days with high fever and heavy septicemia. 
All three  monkeys were killed just after their  temperature  had  returned  to 
normal, and all showed perfectly normal lungs. 
This  experiment  has  considerable  significance  in  suggesting  that 
distinction must be made between a humoral immunity against pneu- 
mococcus and a  local immunity, possibly cellular, in the lungs.  The 
same  dose  of culture  which  Monkeys  104  and  105  received  intra- 
venously with impunity would have produced a  severe pneumonia if 
administered  intratracheally.  Although  this  phenomenon  may  at .< 
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first seem paradoxical, it is in reality not out of harmony with the 
results obtained in the preceding experiments in which it has been 
clearly  shown  that  prophylactic  vaccination  prevented  to  a  large 
extent  the  development of  septicemia  during  the  course  of  lobar 
pneumonia.  It furthermore demonstrates that tests of the prophy- 
lactic value of vaccination in animals may lead to false conclusions 
if these depend upon the demonstration of immunity to intravenous 
infection rather than to the actual disease against which the vaccina- 
tion is directed. 
DISCUSSION. 
In this study all efforts to protect monkeys against pneumonia by 
subcutaneous vaccination with killed cultures of pneumococcus have 
failed.  With our present ignorance concerning the nature of bacterial 
antigen, any investigation of this nature  must necessarily be for the 
most part empirical.  Inthe experiments reported, two kinds of vaccine 
have been tried--the oily and the saline.  But obviously, many other 
factors determine the  character  of a  vaccine,  each of which should 
be  considered in determining the value of the vaccine for prophy- 
lactic inoculation.  Among these factors are the following: 
Virulence of the Organism.--It has generally been assumed that a 
virulent organism produces a more efficient vaccine than an avirulent 
strain.  The virulent strain, however, causes a more severe reaction, 
and for this reason most vaccines in general use  are prepared  from 
avirulent cultures.  The question of whether a vaccine prepared from 
a  highly virulent pneumococcus will  afford  better  protection than 
one prepared from an avirulent strain has not been attacked in the 
present study.  It may, however, be a more important factor than is 
generally assumed and it is hoped that this question can be investi- 
gated at a later time. 
Method of Cultivation.--When  vaccines are prepared from cultures 
grown on solid media, all  the products of bacterial metabolism are 
presumably included in the vaccine.  When, however, the bacteria 
are grown in liquid media, the supernatant fluid is discarded, and with 
it the bacterial metabolites.  Just how much antigenic value these 
products  have  is  problematical.  It  is  obvious,  moreover,  that  in 
vaccines prepared from broth media, the longer the period of incu- SS0  EXPEI~I"ME.NTAL  PNEUMONIA.  IV 
bation,  the  greater  the  autolysis  and  the  greater  the  amount  of 
bacterial products in solution in the broth.  The influence of sugars, 
animal  sera,  etc.,  when  added  to  the  culture medium may be an 
important factor in the quality of a vaccine. 
Method of Killing the Bacteria.--Many methods have been used for 
killing the bacteria in vaccines, but heat and germicides remain the 
two most frequently employed.  In the case of the lipovaccine and 
saline vaccine used in the present study the pneumococci were killed 
by heat; but in the lipovaccine the bacteria were heated for 24 hours 
at 53°C., whereas in the preparation of the saline vaccine they were 
heated  for  only  1  hour  at  55'C.  Whether  this  difference in  the 
duration of heating had any effect on the antigenic value of the vac- 
clue, it is impossible to say. 
Vehicle in Which the Bacteria Are Suspended.--Untll quite recently 
all vaccines were prepared in  either water  or normal salt  solution. 
The employment of vegetable oils as a  vehicle for suspending bac- 
teria introduces a  new factor into the question of antigenic value. 
It is possible that in oily vaccines a capsule forms around the body of 
the microorganism and interferes not only with its  absorption but 
also with the production of specific antibodies.  In these experiments 
monkeys injected with  pneumococcus lipovaccine failed to develop 
demonstrable agglutinins and protective bodies. 
Age  of the  Vaccine.--The  age  of  the vaccine is undoubtedly an 
important  factor  in  its  antigenic  value and one that has not been 
thoroughly investigated.  The lipovaccine used in the first of these 
experiments was 4 months old at the time the experiment was started. 
In the later  experiments a  fresh lipo,¢accine was used, prepared in 
the same way as the older one, and no difference in effect was ob- 
served in the two vaccines.  With the saline Vaccine, the first experi- 
ment, which was carried out immediately after the vaccine was pre- 
pared,  showed protective bodies in  the  three monkeys tested.  A 
month later the same vaccine was used for testing the effect of three 
repeated injections of saline vaccine and no protective bodies could 
be demonstrated in any of the five monkeys vaccinated.  Whether 
this was a  matter of individual variation in the monkeys or whether 
there  occurred  certain  changes  in  the  vaccine  due  to  standing  I 
month in the ice box, it is hard to say.  The former hypothesis would 
appear more reasonable. RUSSELL L. CECIL AND FRANCIS  G. BLAKE  551 
The  results  obtained  in  this  study  of  prophylactic  vaccination 
against pneumonia in monkeys have been disappointing; but it should 
be borne in mind that the test applied has been a particularly crucial 
one.  Comparatively small doses of vaccine have been used in order 
to  make  the  results  comparable with  vaccination  in  man.  No 
doubt a satisfactory immunity could have been obtained if repeated 
injections of large doses of vaccine had been administered, and still 
better results might have been reached if, in the case of saline vaccine, 
the injections had been given intravenously.  Such an accomplish- 
ment, however, was not the aim of the investigation. 
Furthermore,  the Type I  pneumococcus which was employed in 
the intratracheal injections was an organism of extraordinary viru- 
lence.  It practically never failed to produce the disease even in doses 
of 0.000001  cc. of broth culture, and in unvaccinated monkeys the 
result  was  usually fatal.  One  hundred millionth of  a  cc.  was  in 
most cases lethal for a mouse. 
Finally, it  must  be  emphasized that  the monkey is  highly sus- 
ceptible  to  the  pneumococcus.  The prevalence of  respiratory  in- 
fections among these animals is well known; and that they succumb 
readily to the pneumococcus is evidenced by the fact that an epidemic 
of  Pneumococcus Type  IV pneumonia broke out  among our stock 
monkeys and killed between 30 and 40 of them in less than 4 weeks. 
The disease ran through these animals,  fresh from the Tropics,  in 
very much the same manner that measles and pneumonia ravaged 
our southern recruits in 1917 and 1918.  In either instance it was a 
case where an  organism  was  suddenly brought  in  contact  with  a 
disease to which it had not been previously exposed.  These monkeys 
when living in their natural environment probably rarely encountered 
the pneumococcus and had acquired no racial immunity to pneumo- 
coccus  infections.  Man,  on  the  other  hand,  at  least  in  North 
America,  and particularly in Urban  communities, is  constantly ex- 
posed to pneumococcus infections,  and by reason of this  exposure 
has probably gradually built up a  fair degree of immunity against 
the microorganism.  Clough  is has recently shown that 19 per cent of 
normal men have demonstrable protective substances against pneu- 
12 Clough, P. W., Y. Am. Med. Assn., 1919, lxxiii, 785. 552  EXPERIMENTAL PNEUMONIA.  IV 
mococcus  in  their  serum.  Lack  of  previous  exposure  to  pneu- 
mococcus is  evidenced in  monkeys by the difficulty which one has 
in  producing protective  substances in their blood. 
A  close analogy exists in this connection between pneumonia and 
typhoid fever.  Metchnikoff and Besredka  is in their study of experi- 
mental typhoid fever found that it was impossible to protect apes 
against the disease by means of killed cultures.  Most of the typhoid 
vaccine, however, used in this country and elsewhere has been com- 
posed of killed bacilli and the results obtained with this vaccine are 
sufficient  justification  for  its  further  use.  To  reason  too  closely, 
therefore, from monkey to man may lead to false conclusions.  The 
bearing of this discussion on the question of prophylactic vaccination 
against pneumonia in man is obvious.  The value of such vaccination 
will have to be finally determined by vaccinating large groups of men 
living  under  approximately  the  same  conditions, and  the  results 
controlled by observations upon similar unvaccinated groups. 
Pneumococcus vaccine probably stimulates in every case the pro- 
duction  of  a  certain  quantity  of  antibody,  an  amount,  however, 
which in monkeys is not sufficient to protect them against pneumonia. 
Usually  the  antibody  production  in  monkeys is  not  of  sufficient 
degree to be demonstrable by any laboratory test.  It is sufficient, 
however, to modify the course of  the disease.  The  bacteremia  is 
distinctly less marked.  In twelve vaccinated monkeys the mortality 
rate  was 41.6  per  cent, while for  seventeen unvaccinated monkeys 
the mortality rate was 76.4  per cent.  Other  evidence for this anti- 
body  production is  furnished  by  the  resistance  which  vaccinated 
monkeys offer to infection by the intravenous route. 
In conclusion, it must be emphasized that immunity is a  purely 
relative term.  Almost any animal's "immunity,"  so called, can be 
overcome by a  sufficiently large injection of virulent bacteria. 
laMetchnikoff, E.,  and  Besredka, A.,  Ann. Inst. Pasteur, 1911, xxv, 931; 
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CONCLUSIONS. 
1.  The subcutaneous inoculation of monkeys with Pneumococcus 
Type I  vaccine in doses  comparable with  those  employed in man 
does not protect them against subsequent attacks of Pneumococcus 
Type  I  pneumonia,  either  spontaneous  or  experimental.  Further- 
more,  the occurrence of Pneumococcus Type IV pneumonia among 
monkeys that have been vaccinated with Pneumococcus Type I lipo- 
vaccine  indicates  that  the  vaccinated  animals  develop  no  cross- 
protection against other types of pneumonia. 
2.  Vaccination does,  however, modify the  course of  the disease. 
Invasion of the blood  stream  by  the pneumococcus in  vaccinated' 
animals  is  usually slight,  and  the proportion  of recoveries is  con- 
siderably higher for vaccinated than for unvaccinated monkeys. 
3.  Pneumococcus saline vaccine produces a greater amount of pro- 
tective substance  in the  serum of the  vaccinated animal than does 
pneumococcus lipovaccine and is probably, therefore, a  better anti- 
gen.  Both, however, fail to protect the animal against pneumococcus 
pneumonia. 
4.  Subcutaneous  vaccination  with  pneumococcus  vaccine  gives 
definite protection  against  experimental  pneumococcus  septicemia. 
In other words, vaccination may induce a humoral immunity without 
protecting against intratracheal infection. 
5.  In view of the fact that monkeys are highly susceptible to pneu- 
mococcus infection, a strict analogy cannot be drawn between pneu- 
mococcus immunity in monkeys and pneumococcus immunity in man, 
since in the latter a considerable amount of resistance already exists, 
probably by reason of repeated exposure to pneumococcus infection. 